galcanezumab


( Last Updated : September 15, 2021)
Generic Name:
galcanezumab
Project Status:
Active
Therapeutic Area:
Prevention of migraine
Manufacturer:
Eli Lilly Canada Inc. (Lilly)
Brand Name:
Emgality
Project Line:
Reimbursement Review
Project Number:
SR0693-000
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Eli Lilly Canada Inc. (Lilly) is requesting reimbursement for EMGALITY® (galcanezumab) for the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Emgality is indicated for the prevention of migraine in adults who have at least four migraine days per month.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open May 05, 2021
Call for patient/clinician input closed June 28, 2021
Clarification:

- Patient input submission received from Migraine Canada Migraine Quebec

Submission received June 03, 2021
Submission accepted  
Review initiated June 18, 2021
Draft CADTH review report(s) provided to sponsor for comment September 02, 2021
Deadline for sponsors comments September 14, 2021
CADTH responses on draft review report(s) provided to sponsor October 15, 2021
Expert committee meeting (initial) October 27, 2021
Draft recommendation issued to sponsor November 08, 2021
To
November 10, 2021